NEW YORK (GenomeWeb News) – Danish genomics and molecular diagnostics firm Exiqon today reported that its third-quarter revenues rose 11 percent year over year.

The company posted sales of DKK30.1 million ($5.2 million) in the quarter ended Sept. 30, up from DKK27.1 million a year ago. Product sales totaled DKK20.7 million, up from DKK19.3 million a year ago. Service revenues were down slightly to DKK5.1 million from DKK5.3 million, and license-based revenues were up to DKK2.1 million from DKK1.2 million. Contract research revenues rose to DKK2.2 million from DKK1.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.